Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solifenacin vs oxybutynin vs placebo in neurogenic detrusor overactivity
2006-005523-42Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Aug 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of solifenacin in detrusor hyperreflexia (DH) (4 arms), sponsored by Astellas Pharma. Primary endpoint: Maximum cystometric capacity change. Started Aug 2007; status: completed.
02
Drugs
solifenacin
03
Conditions
detrusor hyperreflexia (DH)
Beyond the preview
Go deeper on 2006-005523-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005523-42.